BLTE

BELITE BIO, INC

Pharmaceutical Preparations · SIC 2834CIK 1889109Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(78.0M)

EPS (Basic, as reported)

$-2.31

Net Margin FY2025

—

ROE FY2025

-10.1%

Total Equity

$770.0M

Shares Out

39M

Business description

BELITE BIO, INC — Pharmaceutical Preparations. Figures are as reported in each year's original 20-F (foreign private issuer annual report) via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (6) → (78)

Fiscal yearFY2020FY2021⚑FY2022FY2023FY2024FY2025

Research & development(4)(7)(9)(25)(30)(45)

Selling, general & administrative———(7)(10)(39)

General & administrative(2)(2)(4)(7)(10)—

Total operating expenses(6)(10)(13)(32)(40)(84)

Operating income(6)(10)(13)(32)(40)(84)

Interest expense0—0000

Interest & investment income000047

Other income (expense), net000047

Pre-tax income(6)(10)(13)(32)(36)(78)

Income tax expense0——000

Net income(6)(10)(13)(32)(36)(78)

EPS — basic($0.65)($1.01)($0.63)($1.19)($1.18)($2.31)

EPS — diluted($0.65)($1.01)($0.63)($1.19)($1.18)($2.31)

Shares outstanding — basic (M)91020273134

Shares outstanding — diluted (M)91020273134

⚑ Weighted-average shares changed ×2.00 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.